You are here: Industry Insights > AstraZeneca

News List

AstraZeneca announces positive results for heart drug candidate biospectrumasia
August 21, 2019
DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type-2 diabetes
AstraZeneca’s diabetes drug Farxiga performs well in heart failure patients pharmaceutical-technology
August 21, 2019
AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with reduced ejection fraction (HFrEF).
AstraZeneca and Merck’s Lynparza continues to perform well in ovarian cancer pharmaceutical-technology
August 16, 2019
AstraZeneca and Merck have announced that Lynparza (olaparib), the primary product in their ongoing oncology collaboration, has performed better than the standard of care as a first line maintenance treatment for patients with ovarian cancer, regardless o
AstraZeneca announces breakthrough therapy status for Calquence in CLL pharmaceutical-technology
August 15, 2019
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL).
AstraZeneca’s Tagrisso helps lung cancer patients live longer: study expresspharma
August 12, 2019
AstraZeneca reported that a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer without the disease worsening.
AstraZeneca demonstrates Tagrisso’s superiority to other EGFR-TKI drugs pharmaceutical-technology
August 12, 2019
AstraZeneca has published results from its Phase III FLAURA trial showing that in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) its drug Tagrisso (osimertinib) performed better than erlotinib or ...
Aevi Genomic Medicine, AstraZeneca Enter Into License Agreement contractpharma
August 08, 2019
Plans to initiate Phase 2 trial for treatment of Adult Onset Still's Disease and other serious rare and orphan diseases.
Inovalon Implements Platform Initiative for AstraZeneca contractpharma
August 07, 2019
Aims to leverage combination of Avalere Business Unit and the Inovalon ONE Platform towards new value-based solutions.
AstraZeneca and Novartis set to lose out from US drug prices reforms europeanpharmaceuticalreview
July 31, 2019
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
AstraZeneca’s ovarian cancer drug Olaparib gets NICE approval pharmaceutical-technology
July 30, 2019
AstraZeneca has obtained the National Institute for Health and Care Excellence (NICE) approval for use of its olaparib drug as a first-line maintenance therapy to treat gynaecological cancers patients on the National Health Service (NHS) in England, UK.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page